Holen Sie sich die Stockscreener-App
96.72
0.43%
0.41
Handel nachbörslich:
96.72
Schlusskurs vom Vortag:
$96.31
Offen:
$96.31
24-Stunden-Volumen:
367.57K
Relative Volume:
0.45
Marktkapitalisierung:
$5.90B
Einnahmen:
$569.61M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-7.1095
EPS:
-13.6043
Netto-Cashflow:
$54.87M
1W Leistung:
-3.12%
1M Leistung:
-14.43%
6M Leistung:
-10.01%
1J Leistung:
+35.23%
1-Tages-Spanne:
$95.49
$97.85
1-Wochen-Bereich:
$95.24
$104.66
52-Wochen-Spanne:
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
96.72 | 5.92B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Mirum Pharmaceuticals(MIRM.US) Officer Sells US$4 Million in Common Stock - Moomoo
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M - TradingView
Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares - Stock Titan
Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale - Stock Titan
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOL.com
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative? - simplywall.st
Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell - MarketBeat
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next - Yahoo Finance
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management - Stock Titan
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade - Stock Titan
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares - Investing.com
Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan - Stock Titan
(MIRM) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What is HC Wainwright's Forecast for MIRM FY2026 Earnings? - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A 40% Potential Upside for Investors in Rare Disease Therapies - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC) - The Globe and Mail
MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise - Stock Titan
Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Q3 EPS Estimate for Mirum Pharmaceuticals Raised by Analyst - MarketBeat
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold" - MarketBeat
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $118 to $140 - Moomoo
MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165 - webull.com
The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com Nigeria
TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside - TradingView
Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline - Quiver Quantitative
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings - MarketBeat
FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G - Stock Titan
RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating - marketscreener.com
HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):